Rheumatoid Arthritis

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

2 weeks ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

2 weeks ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

2 weeks ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

2 weeks ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson

Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management

2 months ago talkbio0Tagged Chinese Language, Clinical Research, Gan & Lee Pharmaceuticals, Glucagon-Like Peptide 1, GRADUAL-3, innovation, once-monthly, Phase 3, Rheumatoid Arthritis, Weight maintenance regimen

Gan & Lee Pharmaceuticals; Phase 3 clinical study; GRADUAL-3; once-monthly GLP-1 RA; weight management; Chinese innovation

AnaptysBio Halts Phase 2 Ulcerative Colitis Trial; Lyell Immunopharma Secures CAR-T Rights

2 months ago talkbio0Tagged AnaptysBio, CAR-T therapy, Clinical Failure, Clinical Trials, Discontinuation (procedure), Lyell Immunopharma, News [Publication Type], Phase 2 trial, Rheumatoid Arthritis, Rosnilimab, Ulcerative Colitis

AnaptysBio; rosnilimab; ulcerative colitis; Phase 2 trial; clinical failure; trial discontinuation; Lyell Immunopharma; CAR-T therapy; licensing deal; biotech news; rheumatoid arthritis

Elevara Raises $70M to Advance Novel Rheumatoid Arthritis Treatment Targeting Synovial Fibroblasts

3 months ago talkbio0Tagged CDK4/6 inhibitor, Chronic inflammatory disorder, Clinical Trials, Elevara Medicines, ELV001, Forbion, Partner in relationship, Pharma, Rheumatoid Arthritis, Series A financing, Sofinnova, synovial fibroblasts, Teijin

Elevara Medicines; Series A financing; rheumatoid arthritis; ELV001; CDK4/6 inhibitor; synovial fibroblasts; Teijin Pharma; clinical trial; chronic inflammatory diseases; Forbion; Sofinnova Partners

Sanofi Partners with EVOQ Therapeutics to Advance NanoDisc-Based Autoimmune Therapies

3 months ago talkbio0Tagged Autoimmune Diseases, Celiac Disease, Diabetes Mellitus, Insulin-Dependent, EVOQ, Immune Tolerance, License Agreement, Lupus Vulgaris, MOG antibody disease, NanoDisc, Rheumatoid Arthritis, sanofi

Sanofi; EVOQ Therapeutics; NanoDisc; autoimmune disease; license agreement; immune tolerance; celiac disease; type 1 diabetes; MOG antibody disease; rheumatoid arthritis; lupus

Sparrow Pharmaceuticals Raises $95M Series B for Midstage Diabetes Study

4 months ago talkbio0Tagged Capital Management, clofutriben, Diabetes Mellitus, Non-Insulin-Dependent, Forbion, hydrocortisone, Psychological inhibition, Rheumatoid Arthritis, Series B fundraising, SPAG8 gene, Sparrow Pharmaceuticals, venture

Sparrow Pharmaceuticals; Series B fundraising; Type 2 diabetes; clofutriben; phase 2b trial; HSD-1 inhibition; cortisol; RA Capital Management; Forbion; venture capital

J&J Halts Phase 2a Rheumatoid Arthritis Program for Imaavy (Nipocalimab) after Lackluster Results

5 months ago talkbio0Tagged Autoimmune Diseases, Clinical Research, Clinical trial failure, daisy, Imaavy, Johnson and Johnson, Nipocalimab, Phase 2a Trial, Rheumatoid Arthritis

Johnson & Johnson; Imaavy; nipocalimab; rheumatoid arthritis; Phase 2a trial; DAISY study; clinical trial failure; anti-TNFα therapy; autoimmune diseases